Overview

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

Status:
Not yet recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
To learn about the effects of naproxen and aspirin on the normal colon in people with Lynch Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Treatments:
Aspirin
Naproxen